{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:57:02Z","timestamp":1790744222918,"version":"4.1.0"},"reference-count":209,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"DOI":"10.1007\/s10096-026-05686-z","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:45:40Z","timestamp":1790693140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HBV\/HCV coinfection and anti-tuberculosis drug-induced liver injury: from risk assessment and exploration of mechanisms to preventive considerations"],"prefix":"10.1007","author":[{"given":"Xiao-Jing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6685-2167","authenticated-orcid":false,"given":"Guo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"5686_CR1","unstructured":"World Health Organization (2025) Tuberculosis. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis. Accessed 30 April 2026"},{"issue":"7","key":"5686_CR2","doi-asserted-by":"publisher","first-page":"e21836","DOI":"10.1371\/journal.pone.0021836","volume":"6","author":"P Shang","year":"2011","unstructured":"Shang P, Xia Y, Liu F, Wang X, Yuan Y, Hu D et al (2011) Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS ONE 6(7):e21836. https:\/\/doi.org\/10.1371\/journal.pone.0021836","journal-title":"PLoS ONE"},{"key":"5686_CR3","doi-asserted-by":"publisher","first-page":"1811720","DOI":"10.3389\/fmed.2026.1811720","volume":"13","author":"Q Wu","year":"2026","unstructured":"Wu Q, Peng J, Xiao X, Zhou H, Ouyang Y, Chen S et al (2026) Drug-induced liver injury as a strong independent predictor of in-hospital mortality in tuberculous meningitis: potential age-related effect modification suggested in a large lifespan cohort. Front Med (Lausanne) 13:1811720. https:\/\/doi.org\/10.3389\/fmed.2026.1811720","journal-title":"Front Med (Lausanne)"},{"key":"5686_CR4","unstructured":"World Health Organization (2025) WHO operational handbook on tuberculosis: module 4: treatment and care. https:\/\/www.who.int\/publications\/i\/item\/9789240107243. Accessed 1 October 2025"},{"key":"5686_CR5","volume-title":"Global hepatitis report 2026","author":"World Health Organization","year":"2026","unstructured":"World Health Organization (2026) Global hepatitis report 2026. World Health Organization, Geneva. https:\/\/www.who.int\/publications\/i\/item\/9789240122383 Accessed 2 September 2026"},{"issue":"7","key":"5686_CR6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/MCG.0000000000001533","volume":"56","author":"RJ Wong","year":"2022","unstructured":"Wong RJ, Hubbard A, Bagley L, Shiau R, Chitnis AS (2022) Estimating prevalence of hepatitis B virus coinfection among adults with tuberculosis: a systematic review with meta-analysis. J Clin Gastroenterol 56(7):601\u2013617. https:\/\/doi.org\/10.1097\/MCG.0000000000001533","journal-title":"J Clin Gastroenterol"},{"key":"5686_CR7","doi-asserted-by":"publisher","first-page":"101938","DOI":"10.1016\/j.eclinm.2023.101938","volume":"58","author":"ID Olaru","year":"2023","unstructured":"Olaru ID, Beliz Meier M, Mirzayev F, Prodanovic N, Kitchen PJ, Schumacher SG et al (2023) Global prevalence of hepatitis B or hepatitis C infection among patients with tuberculosis disease: systematic review and meta-analysis. EClinicalMedicine 58:101938. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101938","journal-title":"EClinicalMedicine"},{"issue":"6","key":"5686_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.4110\/in.2016.16.6.330","volume":"16","author":"MK Jung","year":"2016","unstructured":"Jung MK, Shin EC (2016) Regulatory T cells in hepatitis B and C virus infections. Immune Netw 16(6):330\u2013336. https:\/\/doi.org\/10.4110\/in.2016.16.6.330","journal-title":"Immune Netw"},{"key":"5686_CR9","doi-asserted-by":"publisher","first-page":"1834524","DOI":"10.3389\/fmed.2026.1834524","volume":"13","author":"X Liu","year":"2026","unstructured":"Liu X, Liu C, Yao R, Wan B, Fu L, Yang X et al (2026) Risk factors for drug-induced liver injury in tuberculosis patients: a meta-analysis and systematic review. Front Med (Lausanne) 13:1834524. https:\/\/doi.org\/10.3389\/fmed.2026.1834524","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"5686_CR10","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/jvh.13751","volume":"29","author":"C Chou","year":"2022","unstructured":"Chou C, Veracruz N, Chitnis AS, Wong RJ (2022) Risk of drug-induced liver injury in chronic hepatitis B and tuberculosis co-infection: a systematic review and meta-analysis. J Viral Hepat 29(12):1107\u20131114. https:\/\/doi.org\/10.1111\/jvh.13751","journal-title":"J Viral Hepat"},{"key":"5686_CR11","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1017\/S0950268820002861","volume":"148","author":"J Zheng","year":"2020","unstructured":"Zheng J, Guo MH, Peng HW, Cai XL, Wu YL, Peng XE (2020) The role of hepatitis B infection in anti-tuberculosis drug-induced liver injury: a meta-analysis of cohort studies. Epidemiol Infect 148:e290. https:\/\/doi.org\/10.1017\/S0950268820002861","journal-title":"Epidemiol Infect"},{"issue":"7","key":"5686_CR12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jcma.2015.12.006","volume":"79","author":"NT Wang","year":"2016","unstructured":"Wang NT, Huang YS, Lin MH, Huang B, Perng CL, Lin HC (2016) Chronic hepatitis B infection and risk of antituberculosis drug-induced liver injury: systematic review and meta-analysis. J Chin Med Assoc 79(7):368\u2013374. https:\/\/doi.org\/10.1016\/j.jcma.2015.12.006","journal-title":"J Chin Med Assoc"},{"issue":"1","key":"5686_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12985-020-01385-z","volume":"17","author":"BE Feleke","year":"2020","unstructured":"Feleke BE, Feleke TE, Adane WG, Girma A (2020) Impacts of hepatitis B and hepatitis C co-infection with tuberculosis, a prospective cohort study. Virol J 17(1):113. https:\/\/doi.org\/10.1186\/s12985-020-01385-z","journal-title":"Virol J"},{"issue":"6","key":"5686_CR14","doi-asserted-by":"publisher","first-page":"800","DOI":"10.5588\/ijtld.15.0668","volume":"20","author":"SS Lee","year":"2016","unstructured":"Lee SS, Lee CM, Kim TH, Kim JJ, Lee JM, Kim HJ et al (2016) Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 20(6):800\u2013805. https:\/\/doi.org\/10.5588\/ijtld.15.0668","journal-title":"Int J Tuberc Lung Dis"},{"key":"5686_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12879-016-1344-2","volume":"16","author":"WS Kim","year":"2016","unstructured":"Kim WS, Lee SS, Lee CM, Kim HJ, Ha CY, Kim HJ et al (2016) Hepatitis C and not hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infect Dis 16:50. https:\/\/doi.org\/10.1186\/s12879-016-1344-2","journal-title":"BMC Infect Dis"},{"issue":"12","key":"5686_CR16","doi-asserted-by":"publisher","first-page":"e83892","DOI":"10.1371\/journal.pone.0083892","volume":"8","author":"N Lomtadze","year":"2013","unstructured":"Lomtadze N, Kupreishvili L, Salakaia A, Vashakidze S, Sharvadze L, Kempker RR et al (2013) Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis. PLoS ONE 8(12):e83892. https:\/\/doi.org\/10.1371\/journal.pone.0083892","journal-title":"PLoS ONE"},{"issue":"5","key":"5686_CR17","first-page":"616","volume":"14","author":"JY Chien","year":"2010","unstructured":"Chien JY, Huang RM, Wang JY, Ruan SY, Chien YJ, Yu CJ et al (2010) Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment. Int J Tuberc Lung Dis 14(5):616\u2013621","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"5686_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/s0929-6646(09)60040-1","volume":"108","author":"HY Sun","year":"2009","unstructured":"Sun HY, Chen YJ, Gau CS, Chang SC, Luh KT (2009) A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature. J Formos Med Assoc 108(2):102\u2013111. https:\/\/doi.org\/10.1016\/s0929-6646(09)60040-1","journal-title":"J Formos Med Assoc"},{"issue":"2","key":"5686_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1183\/09031936.00090306","volume":"29","author":"KC Chang","year":"2007","unstructured":"Chang KC, Leung CC, Yew WW, Tam CM (2007) Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter? Eur Respir J 29(2):347\u2013351. https:\/\/doi.org\/10.1183\/09031936.00090306","journal-title":"Eur Respir J"},{"issue":"1","key":"5686_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/hep.510310129","volume":"31","author":"WM Wong","year":"2000","unstructured":"Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC et al (2000) Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 31(1):201\u2013206. https:\/\/doi.org\/10.1002\/hep.510310129","journal-title":"Hepatology"},{"issue":"8","key":"5686_CR21","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/pds.3988","volume":"25","author":"Q Sun","year":"2016","unstructured":"Sun Q, Zhang Q, Gu J, Sun WW, Wang P, Bai C et al (2016) Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study. Pharmacoepidemiol Drug Saf 25(8):908\u2013917. https:\/\/doi.org\/10.1002\/pds.3988","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"5686_CR22","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/jvh.12583","volume":"23","author":"C Trigo","year":"2016","unstructured":"Trigo C, do Brasil PE, Costa MJ, de Castro L (2016) Occult hepatitis B virus infection: clinical implications in tuberculosis treatment. J Viral Hepat 23(12):1027\u20131035. https:\/\/doi.org\/10.1111\/jvh.12583","journal-title":"J Viral Hepat"},{"issue":"5","key":"5686_CR23","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/j.1572-0241.2002.05704.x","volume":"97","author":"PA Patel","year":"2002","unstructured":"Patel PA, Voigt MD (2002) Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 97(5):1198\u20131203. https:\/\/doi.org\/10.1111\/j.1572-0241.2002.05704.x","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"5686_CR24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jinf.2011.04.005","volume":"62","author":"JY Wang","year":"2011","unstructured":"Wang JY, Liu CH, Hu FC, Chang HC, Liu JL, Chen JM et al (2011) Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect 62(6):448\u2013455. https:\/\/doi.org\/10.1016\/j.jinf.2011.04.005","journal-title":"J Infect"},{"issue":"1","key":"5686_CR25","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1186\/s12879-025-12005-y","volume":"25","author":"X Wei","year":"2025","unstructured":"Wei X, Cai R, Wu X, Su Y, Lian S, Nan T et al (2025) Risk of drug-induced liver injury in chronic hepatitis C and tuberculosis co-infection: a systematic review and meta-analysis. BMC Infect Dis 25(1):1566. https:\/\/doi.org\/10.1186\/s12879-025-12005-y","journal-title":"BMC Infect Dis"},{"issue":"6","key":"5686_CR26","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/aje\/kwag024","volume":"195","author":"A LaHood","year":"2026","unstructured":"LaHood A, Robins J, Stagg HR, Sauer S, Ahmed S, Bastard M et al (2026) Estimating the effect of hepatitis C infection on multidrug-resistant tuberculosis treatment outcomes under hypothetical interventions on regimen composition and adherence. Am J Epidemiol 195(6):1615\u20131623. https:\/\/doi.org\/10.1093\/aje\/kwag024","journal-title":"Am J Epidemiol"},{"issue":"6","key":"5686_CR27","doi-asserted-by":"publisher","first-page":"e110655","DOI":"10.1164\/ajrccm.157.6.9711039","volume":"18","author":"H Khan","year":"2026","unstructured":"Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP et al (1998) Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 157(6 Pt 1):1871\u20131876. https:\/\/doi.org\/10.1164\/ajrccm.157.6.9711039","journal-title":"Cureus"},{"issue":"2","key":"5686_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jcma.2017.10.002","volume":"81","author":"TE Chang","year":"2018","unstructured":"Chang TE, Huang YS, Chang CH, Perng CL, Huang YH, Hou MC (2018) The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: a systematic review and meta-analysis. J Chin Med Assoc 81(2):111\u2013118. https:\/\/doi.org\/10.1016\/j.jcma.2017.10.002","journal-title":"J Chin Med Assoc"},{"issue":"1","key":"5686_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3904\/kjim.2016.31.1.65","volume":"31","author":"CM Lee","year":"2016","unstructured":"Lee CM, Lee SS, Lee JM, Cho HC, Kim WS, Kim HJ et al (2016) Early monitoring for detection of antituberculous drug-induced hepatotoxicity. Korean J Intern Med 31(1):65\u201372. https:\/\/doi.org\/10.3904\/kjim.2016.31.1.65","journal-title":"Korean J Intern Med"},{"issue":"6 Pt 1","key":"5686_CR30","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.7759\/cureus.110655","volume":"157","author":"JR Ungo","year":"1998","unstructured":"Khan H, Arif M, Aftab F, Khan A, Diwaya IA, Farooq Sherazi SH et al (2026) Risk factors and clinical predictors of drug-induced hepatotoxicity in patients receiving first-line anti-tuberculosis therapy. Cureus 18(6):e110655. https:\/\/doi.org\/10.7759\/cureus.110655","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"5686_CR31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","volume":"23","author":"A Tostmann","year":"2008","unstructured":"Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R (2008) Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 23(2):192\u2013202. https:\/\/doi.org\/10.1111\/j.1440-1746.2007.05207.x","journal-title":"J Gastroenterol Hepatol"},{"key":"5686_CR32","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.coviro.2021.10.003","volume":"51","author":"KN Tsai","year":"2021","unstructured":"Tsai KN, Ou JJ (2021) Hepatitis B virus e antigen and viral persistence. Curr Opin Virol 51:158\u2013163. https:\/\/doi.org\/10.1016\/j.coviro.2021.10.003","journal-title":"Curr Opin Virol"},{"issue":"4","key":"5686_CR33","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1378\/chest.127.4.1304","volume":"127","author":"BH Lee","year":"2005","unstructured":"Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H et al (2005) Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 127(4):1304\u20131311. https:\/\/doi.org\/10.1378\/chest.127.4.1304","journal-title":"Chest"},{"issue":"1","key":"5686_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12879-018-3192-8","volume":"18","author":"L Chen","year":"2018","unstructured":"Chen L, Bao D, Gu L, Gu Y, Zhou L, Gao Z et al (2018) Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment. BMC Infect Dis 18(1):295. https:\/\/doi.org\/10.1186\/s12879-018-3192-8","journal-title":"BMC Infect Dis"},{"issue":"1","key":"5686_CR35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/cid\/ciae169","volume":"79","author":"JB Bertumen","year":"2024","unstructured":"Bertumen JB, Pascopella L, Han E, Glenn-Finer R, Wong RJ, Chitnis A et al (2024) Epidemiology and treatment outcomes of tuberculosis with chronic hepatitis B infection-California, 2016\u20132020. Clin Infect Dis 79(1):223\u2013232. https:\/\/doi.org\/10.1093\/cid\/ciae169","journal-title":"Clin Infect Dis"},{"key":"5686_CR36","doi-asserted-by":"publisher","unstructured":"Bhattacharya D, Aronsohn A, Price J, Lo Re V (2023) Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciad319","DOI":"10.1093\/cid\/ciad319"},{"issue":"1","key":"5686_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/jvh.13204","volume":"27","author":"TL Laursen","year":"2020","unstructured":"Laursen TL, Siggaard CB, Kazankov K, Sandahl TD, M\u00f8ller HJ, Tarp B et al (2020) Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C. J Viral Hepat 27(1):28\u201335. https:\/\/doi.org\/10.1111\/jvh.13204","journal-title":"J Viral Hepat"},{"issue":"12","key":"5686_CR38","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1128\/JCM.40.12.4407-4412.2002","volume":"40","author":"SS Richter","year":"2002","unstructured":"Richter SS (2002) Laboratory assays for diagnosis and management of hepatitis C virus infection. J Clin Microbiol 40(12):4407\u20134412. https:\/\/doi.org\/10.1128\/JCM.40.12.4407-4412.2002","journal-title":"J Clin Microbiol"},{"key":"5686_CR39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijid.2014.06.020","volume":"28","author":"P Mo","year":"2014","unstructured":"Mo P, Zhu Q, Teter C, Yang R, Deng L, Yan Y et al (2014) Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus. Int J Infect Dis 28:95\u2013100. https:\/\/doi.org\/10.1016\/j.ijid.2014.06.020","journal-title":"Int J Infect Dis"},{"issue":"12","key":"5686_CR40","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.5588\/ijtld.18.0195","volume":"22","author":"AP Chua","year":"2018","unstructured":"Chua AP, Lim LK, Gan SH, Chee CB, Wang YT (2018) The role of chronic viral hepatitis on tuberculosis treatment interruption. Int J Tuberc Lung Dis 22(12):1486\u20131494. https:\/\/doi.org\/10.5588\/ijtld.18.0195","journal-title":"Int J Tuberc Lung Dis"},{"issue":"D1","key":"5686_CR41","doi-asserted-by":"publisher","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","volume":"53","author":"S Jiang","year":"2025","unstructured":"Jiang S, Li H, Zhang L, Mu W, Zhang Y, Chen T et al (2025) Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res 53(D1):D1670\u2013D1676. https:\/\/doi.org\/10.1093\/nar\/gkae973","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"5686_CR42","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"European Association for the Study of the Liver","year":"2019","unstructured":"European Association for the Study of the Liver (2019) EASL clinical practice guidelines: Drug-induced liver injury. J Hepatol 70(6):1222\u20131261. https:\/\/doi.org\/10.1016\/j.jhep.2019.02.014","journal-title":"J Hepatol"},{"key":"5686_CR43","doi-asserted-by":"publisher","first-page":"111160","DOI":"10.1016\/j.cbi.2024.111160","volume":"400","author":"Y Masubuchi","year":"2024","unstructured":"Masubuchi Y, Miyauchi K (2024) Metabolism-dependent inhibition of CYP2E1 by isoniazid, a mediator of idiosyncratic liver injury. Chem Biol Interact 400:111160. https:\/\/doi.org\/10.1016\/j.cbi.2024.111160","journal-title":"Chem Biol Interact"},{"issue":"11","key":"5686_CR44","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1021\/tx300341r","volume":"25","author":"IG Metushi","year":"2012","unstructured":"Metushi IG, Nakagawa T, Uetrecht J (2012) Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats. Chem Res Toxicol 25(11):2567\u20132576. https:\/\/doi.org\/10.1021\/tx300341r","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"5686_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1021\/tx500285k","volume":"28","author":"X Meng","year":"2015","unstructured":"Meng X, Maggs JL, Usui T, Whitaker P, French NS, Naisbitt DJ et al (2015) Auto-oxidation of isoniazid leads to isonicotinic-lysine adducts on human serum albumin. Chem Res Toxicol 28(1):51\u201358. https:\/\/doi.org\/10.1021\/tx500285k","journal-title":"Chem Res Toxicol"},{"key":"5686_CR46","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.freeradbiomed.2013.07.038","volume":"65","author":"KK Lee","year":"2013","unstructured":"Lee KK, Fujimoto K, Zhang C, Schwall CT, Alder NN, Pinkert CA et al (2013) Isoniazid-induced cell death is precipitated by underlying mitochondrial complex I dysfunction in mouse hepatocytes. Free Radic Biol Med 65:584\u2013594. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2013.07.038","journal-title":"Free Radic Biol Med"},{"key":"5686_CR47","doi-asserted-by":"publisher","first-page":"111448","DOI":"10.1016\/j.cbi.2025.111448","volume":"411","author":"TTM Nhung","year":"2025","unstructured":"Nhung TTM, Phat NK, Anh TT, Nghi TD, Thu NQ, Lee A et al (2025) Endoplasmic reticulum stress inhibition preserves mitochondrial function and cell survival during the early onset of isoniazid-induced oxidative stress. Chem Biol Interact 411:111448. https:\/\/doi.org\/10.1016\/j.cbi.2025.111448","journal-title":"Chem Biol Interact"},{"issue":"5","key":"5686_CR48","doi-asserted-by":"publisher","first-page":"e01639","DOI":"10.1128\/AAC.01639-18","volume":"63","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Cen J, Jia Z, Hsiao CD, Xia Q, Wang X et al (2019) Hepatotoxicity induced by isoniazid-lipopolysaccharide through endoplasmic reticulum stress, autophagy, and apoptosis pathways in zebrafish. Antimicrob Agents Chemother 63(5):e01639\u2013e01618. https:\/\/doi.org\/10.1128\/AAC.01639-18","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"5686_CR49","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1124\/dmd.121.000389","volume":"49","author":"Z Hussain","year":"2021","unstructured":"Hussain Z, Zhu J, Ma X (2021) Metabolism and hepatotoxicity of pyrazinamide, an antituberculosis drug. Drug Metab Dispos 49(8):679\u2013682. https:\/\/doi.org\/10.1124\/dmd.121.000389","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"5686_CR50","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/toxres\/tfaa015","volume":"9","author":"Y Xu","year":"2020","unstructured":"Xu Y, Jiang Y, Li Y (2020) Pyrazinamide enhances lipid peroxidation and antioxidant levels to induce liver injury in rat models through PI3k\/Akt inhibition. Toxicol Res (Camb) 9(3):149\u2013157. https:\/\/doi.org\/10.1093\/toxres\/tfaa015","journal-title":"Toxicol Res (Camb)"},{"issue":"2","key":"5686_CR51","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/s0016-5085(00)70224-1","volume":"118","author":"B Stieger","year":"2000","unstructured":"Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ (2000) Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118(2):422\u2013430. https:\/\/doi.org\/10.1016\/s0016-5085(00)70224-1","journal-title":"Gastroenterology"},{"issue":"5","key":"5686_CR52","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3109\/15376516.2015.1033074","volume":"25","author":"YX Guo","year":"2015","unstructured":"Guo YX, Xu XF, Zhang QZ, Li C, Deng Y, Jiang P et al (2015) The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid\/rifampicin-induced hepatotoxicity. Toxicol Mech Methods 25(5):382\u2013387. https:\/\/doi.org\/10.3109\/15376516.2015.1033074","journal-title":"Toxicol Mech Methods"},{"issue":"1","key":"5686_CR53","doi-asserted-by":"publisher","first-page":"481","DOI":"10.7150\/ijbs.109757","volume":"22","author":"J Chen","year":"2026","unstructured":"Chen J, Zhang Q, Huang J, He H, Bai Y, An Y et al (2026) Integrated single-cell transcriptomics and proteomics elucidate the molecular mechanisms and detoxification strategy of rifampicin-induced hepatotoxicity. Int J Biol Sci 22(1):481\u2013499. https:\/\/doi.org\/10.7150\/ijbs.109757","journal-title":"Int J Biol Sci"},{"issue":"4","key":"5686_CR54","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/sj.bjp.0707611","volume":"153","author":"C Shen","year":"2008","unstructured":"Shen C, Meng Q, Zhang G, Hu W (2008) Rifampicin exacerbates isoniazid-induced toxicity in human but not in rat hepatocytes in tissue-like cultures. Br J Pharmacol 153(4):784\u2013791. https:\/\/doi.org\/10.1038\/sj.bjp.0707611","journal-title":"Br J Pharmacol"},{"issue":"1","key":"5686_CR55","first-page":"145","volume":"3","author":"A Mak","year":"2017","unstructured":"Mak A, Uetrecht J (2017) Immune mechanisms of idiosyncratic drug-induced liver injury. J Clin Transl Res 3(1):145\u2013156","journal-title":"J Clin Transl Res"},{"issue":"3","key":"5686_CR56","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/hep.26564","volume":"59","author":"IG Metushi","year":"2014","unstructured":"Metushi IG, Sanders C, Acute Liver Study Group, Lee WM, Uetrecht J (2014) Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology 59(3):1084\u20131093. https:\/\/doi.org\/10.1002\/hep.26564","journal-title":"Hepatology"},{"issue":"8","key":"5686_CR57","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1084\/jem.191.8.1263","volume":"191","author":"B Rehermann","year":"2000","unstructured":"Rehermann B (2000) Intrahepatic T cells in hepatitis B: viral control versus liver cell injury. J Exp Med 191(8):1263\u20131268. https:\/\/doi.org\/10.1084\/jem.191.8.1263","journal-title":"J Exp Med"},{"issue":"3","key":"5686_CR58","doi-asserted-by":"publisher","first-page":"e1694","DOI":"10.1038\/cddis.2015.42","volume":"6","author":"B Ye","year":"2015","unstructured":"Ye B, Liu X, Li X, Kong H, Tian L, Chen Y (2015) T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis 6(3):e1694. https:\/\/doi.org\/10.1038\/cddis.2015.42","journal-title":"Cell Death Dis"},{"key":"5686_CR59","doi-asserted-by":"publisher","first-page":"1506526","DOI":"10.3389\/fimmu.2025.1506526","volume":"16","author":"H Zheng","year":"2025","unstructured":"Zheng H, Xu B, Fan Y, Tuekprakhon A, Stamataki Z, Wang F (2025) The role of immune regulation in HBV infection and hepatocellular carcinogenesis. Front Immunol 16:1506526. https:\/\/doi.org\/10.3389\/fimmu.2025.1506526","journal-title":"Front Immunol"},{"issue":"1","key":"5686_CR60","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/biology15010076","volume":"15","author":"AS Pathania","year":"2025","unstructured":"Pathania AS, Bhat SA, Adepoju LA, Kharbanda KK, Osna NA (2025) Hepatic macrophages in chronic hepatitis B: balancing immunity and pathology. Biology (Basel) 15(1):76. https:\/\/doi.org\/10.3390\/biology15010076","journal-title":"Biology (Basel)"},{"issue":"4","key":"5686_CR61","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.3892\/ol.2020.11404","volume":"19","author":"LR Ling","year":"2020","unstructured":"Ling LR, Zheng DH, Zhang ZY, Xie WH, Huang YH, Chen ZX et al (2020) Effect of HBx on inflammation and mitochondrial oxidative stress in mouse hepatocytes. Oncol Lett 19(4):2861\u20132869. https:\/\/doi.org\/10.3892\/ol.2020.11404","journal-title":"Oncol Lett"},{"issue":"6","key":"5686_CR62","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1128\/jvi.74.6.2840-2846.2000","volume":"74","author":"Z Rahmani","year":"2000","unstructured":"Rahmani Z, Huh KW, Lasher R, Siddiqui A (2000) Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent anion channel, HVDAC3, and alters its transmembrane potential. J Virol 74(6):2840\u20132846. https:\/\/doi.org\/10.1128\/jvi.74.6.2840-2846.2000","journal-title":"J Virol"},{"key":"5686_CR63","doi-asserted-by":"publisher","first-page":"1786614","DOI":"10.3389\/fphar.2026.1786614","volume":"17","author":"L An","year":"2026","unstructured":"An L, Han Y, Sun X, Wang L, Guo L (2026) Protein quality control and antigen presentation in the development of hepatitis B-related hepatocellular carcinoma. Front Pharmacol 17:1786614. https:\/\/doi.org\/10.3389\/fphar.2026.1786614","journal-title":"Front Pharmacol"},{"issue":"36","key":"5686_CR64","doi-asserted-by":"publisher","first-page":"8161","DOI":"10.3748\/wjg.v22.i36.8161","volume":"22","author":"YX Shi","year":"2016","unstructured":"Shi YX, Huang CJ, Yang ZG (2016) Impact of hepatitis B virus infection on hepatic metabolic signaling pathway. World J Gastroenterol 22(36):8161\u20138167. https:\/\/doi.org\/10.3748\/wjg.v22.i36.8161","journal-title":"World J Gastroenterol"},{"issue":"1","key":"5686_CR65","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41419-025-08019-8","volume":"16","author":"ZB Du","year":"2025","unstructured":"Du ZB, Han T, Cai YX, Shen YS, Wu JS, Li X et al (2025) Hepatic steatosis and pyroptosis are induced by the hepatitis B virus X protein via B56\u03b1-METTL3 interaction-mediated m6A modification of the NLRP3 mRNA. Cell Death Dis 16(1):698. https:\/\/doi.org\/10.1038\/s41419-025-08019-8","journal-title":"Cell Death Dis"},{"issue":"8","key":"5686_CR66","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3390\/v9080230","volume":"9","author":"S Lin","year":"2017","unstructured":"Lin S, Zhang YJ (2017) Interference of apoptosis by hepatitis B virus. Viruses 9(8):230. https:\/\/doi.org\/10.3390\/v9080230","journal-title":"Viruses"},{"issue":"1","key":"5686_CR67","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2119\/molmed.2013.00099","volume":"19","author":"R Chen","year":"2013","unstructured":"Chen R, Hou W, Zhang Q, Kang R, Fan XG, Tang D (2013) Emerging role of high-mobility group box 1 (HMGB1) in liver diseases. Mol Med 19(1):357\u2013366. https:\/\/doi.org\/10.2119\/molmed.2013.00099","journal-title":"Mol Med"},{"issue":"2","key":"5686_CR68","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10565-021-09684-z","volume":"39","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Qu Y, Zhang Q, Li F, Li B, Li Z et al (2023) Exosomes derived from hepatitis B virus-infected hepatocytes promote liver fibrosis via miR-222\/TFRC axis. Cell Biol Toxicol 39(2):467\u2013481. https:\/\/doi.org\/10.1007\/s10565-021-09684-z","journal-title":"Cell Biol Toxicol"},{"issue":"3","key":"5686_CR69","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.cell.2015.03.005","volume":"161","author":"LG Guidotti","year":"2015","unstructured":"Guidotti LG, Inverso D, Sironi L, Di Lucia P, Fioravanti J, Ganzer L et al (2015) Immunosurveillance of the liver by intravascular effector CD8(+) T cells. Cell 161(3):486\u2013500. https:\/\/doi.org\/10.1016\/j.cell.2015.03.005","journal-title":"Cell"},{"key":"5686_CR70","unstructured":"World Health Organization (2026) Hepatitis C. World Health Organization, Geneva. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed 2 September 2026"},{"issue":"47","key":"5686_CR71","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.3748\/wjg.v24.i47.5297","volume":"24","author":"H Li","year":"2018","unstructured":"Li H, Huang MH, Jiang JD, Peng ZG (2018) Hepatitis C: from inflammatory pathogenesis to anti-inflammatory\/hepatoprotective therapy. World J Gastroenterol 24(47):5297\u20135311. https:\/\/doi.org\/10.3748\/wjg.v24.i47.5297","journal-title":"World J Gastroenterol"},{"issue":"45","key":"5686_CR72","doi-asserted-by":"publisher","first-page":"37481","DOI":"10.1074\/jbc.M506412200","volume":"280","author":"M Korenaga","year":"2005","unstructured":"Korenaga M, Wang T, Li Y, Showalter LA, Chan T, Sun J et al (2005) Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 280(45):37481\u201337488. https:\/\/doi.org\/10.1074\/jbc.M506412200","journal-title":"J Biol Chem"},{"key":"5686_CR73","doi-asserted-by":"publisher","first-page":"8341937","DOI":"10.1155\/2016\/8341937","volume":"2016","author":"OA Smirnova","year":"2016","unstructured":"Smirnova OA, Ivanova ON, Bartosch B, Valuev-Elliston VT, Mukhtarov F, Kochetkov SN et al (2016) Hepatitis C virus NS5A protein triggers oxidative stress by inducing NADPH oxidases 1 and 4 and cytochrome P450 2E1. Oxid Med Cell Longev 2016:8341937. https:\/\/doi.org\/10.1155\/2016\/8341937","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"5686_CR74","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.3390\/v7062745","volume":"7","author":"AV Ivanov","year":"2015","unstructured":"Ivanov AV, Smirnova OA, Petrushanko IY, Ivanova ON, Karpenko IL, Alekseeva E et al (2015) HCV core protein uses multiple mechanisms to induce oxidative stress in human hepatoma Huh7 cells. Viruses 7(6):2745\u20132770. https:\/\/doi.org\/10.3390\/v7062745","journal-title":"Viruses"},{"issue":"3","key":"5686_CR75","doi-asserted-by":"publisher","first-page":"954","DOI":"10.3390\/v5030954","volume":"5","author":"C Brault","year":"2013","unstructured":"Brault C, Levy PL, Bartosch B (2013) Hepatitis C virus-induced mitochondrial dysfunctions. Viruses 5(3):954\u2013980. https:\/\/doi.org\/10.3390\/v5030954","journal-title":"Viruses"},{"issue":"11","key":"5686_CR76","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.3390\/v14112521","volume":"14","author":"S Moustafa","year":"2022","unstructured":"Moustafa S, Kassela K, Bampali M, Dovrolis N, Kakkanas A, Beloukas A et al (2022) Hepatitis C core protein induces a genotype-specific susceptibility of hepatocytes to TNF-induced death in vitro and in vivo. Viruses 14(11):2521. https:\/\/doi.org\/10.3390\/v14112521","journal-title":"Viruses"},{"issue":"11","key":"5686_CR77","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.3390\/ijms18112346","volume":"18","author":"OV Masalova","year":"2017","unstructured":"Masalova OV, Lesnova EI, Solyev PN, Zakirova NF, Prassolov VS, Kochetkov SN et al (2017) Modulation of cell death pathways by hepatitis C virus proteins in Huh7.5 hepatoma cells. Int J Mol Sci 18(11):2346. https:\/\/doi.org\/10.3390\/ijms18112346","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5686_CR78","doi-asserted-by":"publisher","first-page":"e84953","DOI":"10.1371\/journal.pone.0084953","volume":"9","author":"W Chen","year":"2014","unstructured":"Chen W, Xu Y, Li H, Tao W, Xiang Y, Huang B et al (2014) HCV genomic RNA activates the NLRP3 inflammasome in human myeloid cells. PLoS ONE 9(1):e84953. https:\/\/doi.org\/10.1371\/journal.pone.0084953","journal-title":"PLoS ONE"},{"issue":"2","key":"5686_CR79","doi-asserted-by":"publisher","first-page":"e1007593","DOI":"10.1371\/journal.ppat.1007593","volume":"15","author":"AA Negash","year":"2019","unstructured":"Negash AA, Olson RM, Griffin S, Gale M Jr (2019) Modulation of calcium signaling pathway by hepatitis C virus core protein stimulates NLRP3 inflammasome activation. PLoS Pathog 15(2):e1007593. https:\/\/doi.org\/10.1371\/journal.ppat.1007593","journal-title":"PLoS Pathog"},{"issue":"10","key":"5686_CR80","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.3390\/v13102076","volume":"13","author":"HS Eisfeld","year":"2021","unstructured":"Eisfeld HS, Simonis A, Winter S, Chhen J, Str\u00f6h LJ, Krey T et al (2021) Viral glycoproteins induce NLRP3 inflammasome activation and pyroptosis in macrophages. Viruses 13(10):2076. https:\/\/doi.org\/10.3390\/v13102076","journal-title":"Viruses"},{"key":"5686_CR81","doi-asserted-by":"publisher","first-page":"788138","DOI":"10.3389\/fimmu.2022.788138","volume":"13","author":"HL Wallace","year":"2022","unstructured":"Wallace HL, Wang L, Gardner CL, Corkum CP, Grant MD, Hirasawa K et al (2022) Crosstalk between pyroptosis and apoptosis in hepatitis C virus-induced cell death. Front Immunol 13:788138. https:\/\/doi.org\/10.3389\/fimmu.2022.788138","journal-title":"Front Immunol"},{"issue":"22","key":"5686_CR82","doi-asserted-by":"publisher","first-page":"12284","DOI":"10.1128\/JVI.01962-13","volume":"87","author":"S Shrivastava","year":"2013","unstructured":"Shrivastava S, Mukherjee A, Ray R, Ray RB (2013) Hepatitis C virus induces interleukin-1\u03b2 (IL-1\u03b2)\/IL-18 in circulatory and resident liver macrophages. J Virol 87(22):12284\u201312290. https:\/\/doi.org\/10.1128\/JVI.01962-13","journal-title":"J Virol"},{"issue":"7","key":"5686_CR83","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3390\/cimb48070687","volume":"48","author":"I Tsomidis","year":"2026","unstructured":"Tsomidis I, Tsakou A, Voumvouraki A, Kouroumalis E (2026) Liver macrophages in the pathogenesis of viral hepatitis. Curr Issues Mol Biol 48(7):687. https:\/\/doi.org\/10.3390\/cimb48070687","journal-title":"Curr Issues Mol Biol"},{"issue":"11","key":"5686_CR84","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1128\/JVI.00050-12","volume":"86","author":"SK Bose","year":"2012","unstructured":"Bose SK, Shrivastava S, Meyer K, Ray RB, Ray R (2012) Hepatitis C virus activates the mTOR\/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance. J Virol 86(11):6315\u20136322. https:\/\/doi.org\/10.1128\/JVI.00050-12","journal-title":"J Virol"},{"key":"5686_CR85","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/1743-422X-8-474","volume":"8","author":"F Parvaiz","year":"2011","unstructured":"Parvaiz F, Manzoor S, Tariq H, Javed F, Fatima K, Qadri I (2011) Hepatitis C virus infection: molecular pathways to insulin resistance. Virol J 8:474. https:\/\/doi.org\/10.1186\/1743-422X-8-474","journal-title":"Virol J"},{"issue":"2","key":"5686_CR86","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3390\/ijms23020919","volume":"23","author":"L Perrin-Cocon","year":"2022","unstructured":"Perrin-Cocon L, Kundlacz C, Jacquemin C, Hanoulle X, Aublin-Gex A, Figl M et al (2022) Domain 2 of hepatitis C virus protein NS5A activates glucokinase and induces lipogenesis in hepatocytes. Int J Mol Sci 23(2):919. https:\/\/doi.org\/10.3390\/ijms23020919","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5686_CR87","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12944-019-1136-y","volume":"18","author":"Z Meng","year":"2019","unstructured":"Meng Z, Liu Q, Sun F, Qiao L (2019) Hepatitis C virus nonstructural protein 5A perturbs lipid metabolism by modulating AMPK\/SREBP-1c signaling. Lipids Health Dis 18(1):191. https:\/\/doi.org\/10.1186\/s12944-019-1136-y","journal-title":"Lipids Health Dis"},{"issue":"8","key":"5686_CR88","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/labinvest.2012.88","volume":"92","author":"MV Garc\u00eda-Mediavilla","year":"2012","unstructured":"Garc\u00eda-Mediavilla MV, Pisonero-Vaquero S, Lima-Cabello E, Benedicto I, Majano PL, Jorquera F et al (2012) Liver X receptor \u03b1-mediated regulation of lipogenesis by core and NS5A proteins contributes to HCV-induced liver steatosis and HCV replication. Lab Invest 92(8):1191\u20131202. https:\/\/doi.org\/10.1038\/labinvest.2012.88","journal-title":"Lab Invest"},{"issue":"8","key":"5686_CR89","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.3390\/ijms27083559","volume":"27","author":"J Ferreira","year":"2026","unstructured":"Ferreira J, Caldeira J, Bicho M, Faustino P, Serejo F (2026) Hepatitis C virus: an overview of its chronic impact on liver function, metabolic dysregulation, inflammatory-oxidative pathogenesis and epigenetic memory. Int J Mol Sci 27(8):3559. https:\/\/doi.org\/10.3390\/ijms27083559","journal-title":"Int J Mol Sci"},{"issue":"5","key":"5686_CR90","doi-asserted-by":"publisher","first-page":"101517","DOI":"10.1016\/j.aohep.2024.101517","volume":"29","author":"TG Heredia-Torres","year":"2024","unstructured":"Heredia-Torres TG, Alvarado-Mart\u00ednez V, Rinc\u00f3n-S\u00e1nchez AR, Lozano-Sep\u00falveda SA, Gal\u00e1n-Huerta KA, Arellanos-Soto D et al (2024) Hepatitis C virus NS5A and core protein induce fibrosis-related genes regulation on Huh7 cells through activation of LX2 cells. Ann Hepatol 29(5):101517. https:\/\/doi.org\/10.1016\/j.aohep.2024.101517","journal-title":"Ann Hepatol"},{"issue":"11","key":"5686_CR91","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/j.1365-2893.2010.01362.x","volume":"18","author":"RK Gieseler","year":"2011","unstructured":"Gieseler RK, Marquitan G, Schlattjan M, Sowa JP, Bechmann LP, Timm J et al (2011) Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C. J Viral Hepat 18(11):760\u2013767. https:\/\/doi.org\/10.1111\/j.1365-2893.2010.01362.x","journal-title":"J Viral Hepat"},{"key":"5686_CR92","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.omtn.2019.01.006","volume":"14","author":"JH Kim","year":"2019","unstructured":"Kim JH, Lee CH, Lee SW (2019) Exosomal transmission of microRNA from HCV replicating cells stimulates transdifferentiation in hepatic stellate cells. Mol Ther Nucleic Acids 14:483\u2013497. https:\/\/doi.org\/10.1016\/j.omtn.2019.01.006","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"5686_CR93","doi-asserted-by":"publisher","first-page":"e70178","DOI":"10.1002\/rmv.70178","volume":"36","author":"Z Heydarifard","year":"2026","unstructured":"Heydarifard Z, Shokri S, Mahmoudvand S, Heydarifard F, Parnian R, Mirzaei H (2026) Matrix metalloproteinases and viral hepatitis: a complex interplay driving liver fibrosis, immune dysregulation, and hepatocarcinogenesis. Rev Med Virol 36(4):e70178. https:\/\/doi.org\/10.1002\/rmv.70178","journal-title":"Rev Med Virol"},{"issue":"1","key":"5686_CR94","doi-asserted-by":"publisher","first-page":"e1499","DOI":"10.1002\/wsbm.1499","volume":"13","author":"J Berumen","year":"2021","unstructured":"Berumen J, Baglieri J, Kisseleva T, Mekeel K (2021) Liver fibrosis: pathophysiology and clinical implications. WIREs Mech Dis 13(1):e1499. https:\/\/doi.org\/10.1002\/wsbm.1499","journal-title":"WIREs Mech Dis"},{"issue":"1","key":"5686_CR95","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cbi.2004.09.002","volume":"150","author":"PE Ganey","year":"2004","unstructured":"Ganey PE, Luyendyk JP, Maddox JF, Roth RA (2004) Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact 150(1):35\u201351. https:\/\/doi.org\/10.1016\/j.cbi.2004.09.002","journal-title":"Chem Biol Interact"},{"issue":"1","key":"5686_CR96","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1124\/jpet.108.143792","volume":"328","author":"PJ Shaw","year":"2009","unstructured":"Shaw PJ, Ganey PE, Roth RA (2009) Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin\/lipopolysaccharide coexposure. J Pharmacol Exp Ther 328(1):62\u201368. https:\/\/doi.org\/10.1124\/jpet.108.143792","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"5686_CR97","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/toxsci\/kfr266","volume":"125","author":"J Lu","year":"2012","unstructured":"Lu J, Jones AD, Harkema JR, Roth RA, Ganey PE (2012) Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha. Toxicol Sci 125(1):126\u2013133. https:\/\/doi.org\/10.1093\/toxsci\/kfr266","journal-title":"Toxicol Sci"},{"issue":"12","key":"5686_CR98","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1002\/jat.2979","volume":"34","author":"Y Su","year":"2014","unstructured":"Su Y, Zhang Y, Chen M, Jiang Z, Sun L, Wang T et al (2014) Lipopolysaccharide exposure augments isoniazide-induced liver injury. J Appl Toxicol 34(12):1436\u20131442. https:\/\/doi.org\/10.1002\/jat.2979","journal-title":"J Appl Toxicol"},{"issue":"1","key":"5686_CR99","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/toxsci\/kfm218","volume":"100","author":"PJ Shaw","year":"2007","unstructured":"Shaw PJ, Hopfensperger MJ, Ganey PE, Roth RA (2007) Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Toxicol Sci 100(1):259\u2013266. https:\/\/doi.org\/10.1093\/toxsci\/kfm218","journal-title":"Toxicol Sci"},{"issue":"7","key":"5686_CR100","doi-asserted-by":"publisher","first-page":"e0159512","DOI":"10.1371\/journal.pone.0159512","volume":"11","author":"W Wu","year":"2016","unstructured":"Wu W, Zhao L, Yang P, Zhou W, Li B, Moorhead JF et al (2016) Inflammatory stress sensitizes the liver to atorvastatin-induced injury in ApoE-\/- mice. PLoS ONE 11(7):e0159512. https:\/\/doi.org\/10.1371\/journal.pone.0159512","journal-title":"PLoS ONE"},{"issue":"6","key":"5686_CR101","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/hep.24314","volume":"53","author":"L Fredriksson","year":"2011","unstructured":"Fredriksson L, Herpers B, Benedetti G, Matadin Q, Puigvert JC, de Bont H et al (2011) Diclofenac inhibits tumor necrosis factor-\u03b1-induced nuclear factor-\u03baB activation causing synergistic hepatocyte apoptosis. Hepatology 53(6):2027\u20132041. https:\/\/doi.org\/10.1002\/hep.24314","journal-title":"Hepatology"},{"issue":"3","key":"5686_CR102","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/antiox10030364","volume":"10","author":"M Vairetti","year":"2021","unstructured":"Vairetti M, Di Pasqua LG, Cagna M, Richelmi P, Ferrigno A, Berardo C (2021) Changes in glutathione content in liver diseases: an update. Antioxid (Basel) 10(3):364. https:\/\/doi.org\/10.3390\/antiox10030364","journal-title":"Antioxid (Basel)"},{"issue":"6","key":"5686_CR103","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/s0016-5085(98)70034-4","volume":"115","author":"A Colell","year":"1998","unstructured":"Colell A, Garc\u00eda-Ruiz C, Miranda M, Ardite E, Mar\u00ed M, Morales A et al (1998) Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. Gastroenterology 115(6):1541\u20131551. https:\/\/doi.org\/10.1016\/s0016-5085(98)70034-4","journal-title":"Gastroenterology"},{"issue":"1","key":"5686_CR104","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1053\/jhep.2002.33995","volume":"36","author":"H Nagai","year":"2002","unstructured":"Nagai H, Matsumaru K, Feng G, Kaplowitz N (2002) Reduced glutathione depletion causes necrosis and sensitization to tumor necrosis factor-alpha-induced apoptosis in cultured mouse hepatocytes. Hepatology 36(1):55\u201364. https:\/\/doi.org\/10.1053\/jhep.2002.33995","journal-title":"Hepatology"},{"issue":"6","key":"5686_CR105","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1053\/jhep.2003.50230","volume":"37","author":"K Matsumaru","year":"2003","unstructured":"Matsumaru K, Ji C, Kaplowitz N (2003) Mechanisms for sensitization to TNF-induced apoptosis by acute glutathione depletion in murine hepatocytes. Hepatology 37(6):1425\u20131434. https:\/\/doi.org\/10.1053\/jhep.2003.50230","journal-title":"Hepatology"},{"issue":"3","key":"5686_CR106","doi-asserted-by":"publisher","first-page":"e70660","DOI":"10.1002\/mco2.70660","volume":"7","author":"C Zou","year":"2026","unstructured":"Zou C, Jiang S, Li H, Zhao K, Cao D, Yang G (2026) The NLRP3 inflammasome: mechanisms of activation, regulation, and therapeutic opportunities. MedComm (2020) 7(3):e70660. https:\/\/doi.org\/10.1002\/mco2.70660","journal-title":"MedComm (2020)"},{"key":"5686_CR107","doi-asserted-by":"publisher","first-page":"8086253","DOI":"10.1155\/2021\/8086253","volume":"2021","author":"Q Su","year":"2021","unstructured":"Su Q, Kuang W, Hao W, Liang J, Wu L, Tang C et al (2021) Antituberculosis drugs (rifampicin and isoniazid) induce liver injury by regulating NLRP3 inflammasomes. Mediators Inflamm 2021:8086253. https:\/\/doi.org\/10.1155\/2021\/8086253","journal-title":"Mediators Inflamm"},{"issue":"3","key":"5686_CR108","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.toxlet.2009.11.016","volume":"192","author":"BV Martin-Murphy","year":"2010","unstructured":"Martin-Murphy BV, Holt MP, Ju C (2010) The role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice. Toxicol Lett 192(3):387\u2013394. https:\/\/doi.org\/10.1016\/j.toxlet.2009.11.016","journal-title":"Toxicol Lett"},{"issue":"8","key":"5686_CR109","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.etp.2016.06.005","volume":"68","author":"M Kuramochi","year":"2016","unstructured":"Kuramochi M, Izawa T, Pervin M, Bondoc A, Kuwamura M, Yamate J (2016) The kinetics of damage-associated molecular patterns (DAMPs) and toll-like receptors during thioacetamide-induced acute liver injury in rats. Exp Toxicol Pathol 68(8):471\u2013477. https:\/\/doi.org\/10.1016\/j.etp.2016.06.005","journal-title":"Exp Toxicol Pathol"},{"issue":"1","key":"5686_CR110","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/gut.13.1.47","volume":"13","author":"G Acocella","year":"1972","unstructured":"Acocella G, Bonollo L, Garimoldi M, Mainardi M, Tenconi LT, Nicolis FB (1972) Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut 13(1):47\u201353. https:\/\/doi.org\/10.1136\/gut.13.1.47","journal-title":"Gut"},{"key":"5686_CR111","doi-asserted-by":"publisher","first-page":"8795115","DOI":"10.1155\/2021\/8795115","volume":"2021","author":"S Rajesh","year":"2021","unstructured":"Rajesh S, Philips CA, Ahamed R, Abduljaleel JK, Nair DC, Augustine P (2021) Friend or Foe? Spontaneous portosystemic shunts in cirrhosis-current understanding and future prospects. Can J Gastroenterol Hepatol 2021:8795115. https:\/\/doi.org\/10.1155\/2021\/8795115","journal-title":"Can J Gastroenterol Hepatol"},{"key":"5686_CR112","doi-asserted-by":"publisher","first-page":"1546465","DOI":"10.3389\/fphar.2025.1546465","volume":"16","author":"I Idasiak-Piechocka","year":"2025","unstructured":"Idasiak-Piechocka I, Lewandowski D, \u015awigut W, Kalinowski J, Mikosza K, Suchowiejski P et al (2025) Effect of hypoalbuminemia on drug pharmacokinetics. Front Pharmacol 16:1546465. https:\/\/doi.org\/10.3389\/fphar.2025.1546465","journal-title":"Front Pharmacol"},{"issue":"3","key":"5686_CR113","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/21505594.2016.1141162","volume":"7","author":"M Bartoletti","year":"2016","unstructured":"Bartoletti M, Giannella M, Lewis RE, Viale P (2016) Bloodstream infections in patients with liver cirrhosis. Virulence 7(3):309\u2013319. https:\/\/doi.org\/10.1080\/21505594.2016.1141162","journal-title":"Virulence"},{"issue":"11","key":"5686_CR114","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3390\/pharmaceutics11110578","volume":"11","author":"MF Rasool","year":"2019","unstructured":"Rasool MF, Khalid S, Majeed A, Saeed H, Imran I, Mohany M et al (2019) Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting rifampicin exposure in tuberculosis and cirrhosis populations. Pharmaceutics 11(11):578. https:\/\/doi.org\/10.3390\/pharmaceutics11110578","journal-title":"Pharmaceutics"},{"issue":"1","key":"5686_CR115","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","volume":"66","author":"J Poisson","year":"2017","unstructured":"Poisson J, Lemoinne S, Boulanger C, Durand F, Moreau R, Valla D et al (2017) Liver sinusoidal endothelial cells: physiology and role in liver diseases. J Hepatol 66(1):212\u2013227. https:\/\/doi.org\/10.1016\/j.jhep.2016.07.009","journal-title":"J Hepatol"},{"issue":"4","key":"5686_CR116","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bcp.15990","volume":"90","author":"S Armani","year":"2024","unstructured":"Armani S, Geier A, Forst T, Merle U, Alpers DH, Lunnon MW (2024) Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: impact on pharmacokinetics and drug-drug interactions. Br J Clin Pharmacol 90(4):942\u2013958. https:\/\/doi.org\/10.1111\/bcp.15990","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"5686_CR117","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64(12):1147\u20131161. https:\/\/doi.org\/10.1007\/s00228-008-0553-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"5686_CR118","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1124\/dmd.116.071050","volume":"44","author":"L Wang","year":"2016","unstructured":"Wang L, Collins C, Kelly EJ, Chu X, Ray AS, Salphati L et al (2016) Transporter expression in liver tissue from subjects with alcoholic or hepatitis C cirrhosis quantified by targeted quantitative proteomics. Drug Metab Dispos 44(11):1752\u20131758. https:\/\/doi.org\/10.1124\/dmd.116.071050","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"5686_CR119","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.3390\/cells9112395","volume":"9","author":"M Daujat-Chavanieu","year":"2020","unstructured":"Daujat-Chavanieu M, Gerbal-Chaloin S (2020) Regulation of CAR and PXR expression in health and disease. Cells 9(11):2395. https:\/\/doi.org\/10.3390\/cells9112395","journal-title":"Cells"},{"issue":"12","key":"5686_CR120","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/nchembio.2193","volume":"12","author":"G Levy","year":"2016","unstructured":"Levy G, Habib N, Guzzardi MA, Kitsberg D, Bomze D, Ezra E et al (2016) Nuclear receptors control pro-viral and antiviral metabolic responses to hepatitis C virus infection. Nat Chem Biol 12(12):1037\u20131045. https:\/\/doi.org\/10.1038\/nchembio.2193","journal-title":"Nat Chem Biol"},{"issue":"5","key":"5686_CR121","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.3390\/ijms24054543","volume":"24","author":"M Drozdzik","year":"2023","unstructured":"Drozdzik M, Lapczuk-Romanska J, Wenzel C, Skalski L, Szel\u0105g-Pieniek S, Post M et al (2023) Protein abundance of drug metabolizing enzymes in human hepatitis C livers. Int J Mol Sci 24(5):4543. https:\/\/doi.org\/10.3390\/ijms24054543","journal-title":"Int J Mol Sci"},{"issue":"14","key":"5686_CR122","doi-asserted-by":"publisher","first-page":"7947","DOI":"10.3390\/ijms23147947","volume":"23","author":"M Dro\u017adzik","year":"2022","unstructured":"Dro\u017adzik M, Lapczuk-Romanska J, Wenzel C, Skalski \u0141, Szel\u0105g-Pieniek S, Post M et al (2022) Protein abundance of drug transporters in human hepatitis C livers. Int J Mol Sci 23(14):7947. https:\/\/doi.org\/10.3390\/ijms23147947","journal-title":"Int J Mol Sci"},{"issue":"12","key":"5686_CR123","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.dld.2013.06.004","volume":"45","author":"Y Niu","year":"2013","unstructured":"Niu Y, Wu Z, Shen Q, Song J, Luo Q, You H et al (2013) Hepatitis B virus X protein co-activates pregnane X receptor to induce the cytochrome P450 3A4 enzyme, a potential implication in hepatocarcinogenesis. Dig Liver Dis 45(12):1041\u20131048. https:\/\/doi.org\/10.1016\/j.dld.2013.06.004","journal-title":"Dig Liver Dis"},{"issue":"9","key":"5686_CR124","doi-asserted-by":"publisher","first-page":"e107913","DOI":"10.1371\/journal.pone.0107913","volume":"9","author":"H Liu","year":"2014","unstructured":"Liu H, Lou G, Li C, Wang X, Cederbaum AI, Gan L et al (2014) HBx inhibits CYP2E1 gene expression via downregulating HNF4\u03b1 in human hepatoma cells. PLoS ONE 9(9):e107913. https:\/\/doi.org\/10.1371\/journal.pone.0107913","journal-title":"PLoS ONE"},{"issue":"10","key":"5686_CR125","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1124\/dmd.116.070243","volume":"44","author":"X Tang","year":"2016","unstructured":"Tang X, Ge L, Chen Z, Kong S, Liu W, Xu Y et al (2016) Methylation of the constitutive androstane receptor is involved in the suppression of CYP2C19 in hepatitis B virus-associated hepatocellular carcinoma. Drug Metab Dispos 44(10):1643\u20131652. https:\/\/doi.org\/10.1124\/dmd.116.070243","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"5686_CR126","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.toxlet.2004.09.020","volume":"155","author":"V Haufroid","year":"2005","unstructured":"Haufroid V, Ligocka D, Wallemacq P, Lison D, Horsmans Y (2005) Comparison of cytochrome P4502E1 (CYP2E1) activity and hepatic and lymphocyte mRNA expression in patients with chronic hepatitis C. Toxicol Lett 155(1):171\u2013177. https:\/\/doi.org\/10.1016\/j.toxlet.2004.09.020","journal-title":"Toxicol Lett"},{"issue":"12","key":"5686_CR127","doi-asserted-by":"publisher","first-page":"e01215","DOI":"10.1128\/AAC.01215-19","volume":"63","author":"RR Kempker","year":"2019","unstructured":"Kempker RR, Alghamdi WA, Al-Shaer MH, Burch G, Peloquin CA (2019) A pharmacology perspective of simultaneous tuberculosis and hepatitis C treatment. Antimicrob Agents Chemother 63(12):e01215\u2013e01219","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"5686_CR128","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/cpt.2908","volume":"114","author":"LF Pippa","year":"2023","unstructured":"Pippa LF, Vieira CP, Caris JA, Rocha A, Marques MP, Garcia CP et al (2023) Effect of chronic hepatitis C on the activity of the membrane transporters P-gp and OATP1B1\/BCRP on patients with different stages of hepatic fibrosis. Clin Pharmacol Ther 114(1):173\u2013181. https:\/\/doi.org\/10.1002\/cpt.2908","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"5686_CR129","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.tube.2006.12.001","volume":"87","author":"RC Hartkoorn","year":"2007","unstructured":"Hartkoorn RC, Chandler B, Owen A et al (2007) Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. Tuberculosis (Edinb) 87(3):248\u2013255. https:\/\/doi.org\/10.1016\/j.tube.2006.12.001","journal-title":"Tuberculosis (Edinb)"},{"issue":"4","key":"5686_CR130","doi-asserted-by":"publisher","first-page":"e0215821","DOI":"10.1128\/aac.02158-21","volume":"66","author":"MR Jony","year":"2022","unstructured":"Jony MR, Cho YS, Long NP, Shin HJ, Shin JG (2022) Characterization of clofazimine as a potential substrate of drug transporter. Antimicrob Agents Chemother 66(4):e0215821. https:\/\/doi.org\/10.1128\/aac.02158-21","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"5686_CR131","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3390\/pathogens13090766","volume":"13","author":"A Quirino","year":"2024","unstructured":"Quirino A, Marascio N, Branda F, Ciccozzi A, Romano C, Locci C et al (2024) Viral hepatitis: host immune interaction, pathogenesis and new therapeutic strategies. Pathogens 13(9):766. https:\/\/doi.org\/10.3390\/pathogens13090766","journal-title":"Pathogens"},{"key":"5686_CR132","doi-asserted-by":"publisher","first-page":"1771585","DOI":"10.3389\/fcimb.2026.1771585","volume":"16","author":"C Xiao","year":"2026","unstructured":"Xiao C, Deng Z, Xian P, Huang X, Zou Z, Long L et al (2026) Exploring the partial immunological mechanisms of hepatitis B virus reactivation in patients with hepatitis B and tuberculosis. Front Cell Infect Microbiol 16:1771585. https:\/\/doi.org\/10.3389\/fcimb.2026.1771585","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"5686_CR133","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jceh.2018.06.010","volume":"8","author":"A Arora","year":"2018","unstructured":"Arora A, Anand AC, Kumar A, Singh SP, Aggarwal R, Dhiman RK et al (2018) INASL guidelines on management of hepatitis B virus infection in patients receiving chemotherapy, biologicals, immunosupressants, or corticosteroids. J Clin Exp Hepatol 8(4):403\u2013431. https:\/\/doi.org\/10.1016\/j.jceh.2018.06.010","journal-title":"J Clin Exp Hepatol"},{"issue":"45","key":"5686_CR134","doi-asserted-by":"publisher","first-page":"e40349","DOI":"10.1097\/MD.0000000000040349","volume":"103","author":"H Dong","year":"2024","unstructured":"Dong H, Feng J, Chang X, Wu S, Tang G, Liang F et al (2024) Predictive value of systemic immune-inflammatory biomarkers for drug-induced liver injury in hepatitis B virus surface antigen positive tuberculosis patients: a retrospective observational study. Med (Baltim) 103(45):e40349. https:\/\/doi.org\/10.1097\/MD.0000000000040349","journal-title":"Med (Baltim)"},{"issue":"4","key":"5686_CR135","doi-asserted-by":"publisher","first-page":"240","DOI":"10.14218\/JCTH.2014.00033","volume":"2","author":"L Bojito-Marrero","year":"2014","unstructured":"Bojito-Marrero L, Pyrsopoulos N (2014) Hepatitis B and hepatitis C reactivation in the biologic era. J Clin Transl Hepatol 2(4):240\u2013246. https:\/\/doi.org\/10.14218\/JCTH.2014.00033","journal-title":"J Clin Transl Hepatol"},{"issue":"3","key":"5686_CR136","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/hep.32689","volume":"77","author":"RJ Fontana","year":"2023","unstructured":"Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W et al (2023) AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology 77(3):1036\u20131065. https:\/\/doi.org\/10.1002\/hep.32689","journal-title":"Hepatology"},{"issue":"5","key":"5686_CR137","doi-asserted-by":"publisher","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","volume":"116","author":"NP Chalasani","year":"2021","unstructured":"Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR et al (2021) ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 116(5):878\u2013898. https:\/\/doi.org\/10.14309\/ajg.0000000000001259","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"5686_CR138","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s12072-021-10144-3","volume":"15","author":"H Devarbhavi","year":"2021","unstructured":"Devarbhavi H, Aithal G, Treeprasertsuk S, Takikawa H, Mao Y, Shasthry SM et al (2021) Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int 15(2):258\u2013282. https:\/\/doi.org\/10.1007\/s12072-021-10144-3","journal-title":"Hepatol Int"},{"issue":"8","key":"5686_CR139","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","volume":"174","author":"JJ Saukkonen","year":"2006","unstructured":"Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM et al (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174(8):935\u2013952. https:\/\/doi.org\/10.1164\/rccm.200510-1666ST","journal-title":"Am J Respir Crit Care Med"},{"key":"5686_CR140","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/idr.s8994","volume":"3","author":"JT Denholm","year":"2010","unstructured":"Denholm JT, McBryde ES (2010) The use of anti-tuberculosis therapy for latent TB infection. Infect Drug Resist 3:63\u201372. https:\/\/doi.org\/10.2147\/idr.s8994","journal-title":"Infect Drug Resist"},{"issue":"11","key":"5686_CR141","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/diseases13110355","volume":"13","author":"Z Elharabi","year":"2025","unstructured":"Elharabi Z, Saba J, Akin H (2025) Navigating the latest hepatitis B virus reactivation guidelines. Diseases 13(11):355. https:\/\/doi.org\/10.3390\/diseases13110355","journal-title":"Diseases"},{"issue":"1","key":"5686_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7201a1","volume":"72","author":"EE Conners","year":"2023","unstructured":"Conners EE, Panagiotakopoulos L, Hofmeister MG, Spradling PR, Hagan LM, Harris AM et al (2023) Screening and testing for hepatitis B virus infection: CDC recommendations - United States, 2023. MMWR Recomm Rep 72(1):1\u201325. https:\/\/doi.org\/10.15585\/mmwr.rr7201a1","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"5686_CR143","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12911-026-03373-9","volume":"26","author":"J Feng","year":"2026","unstructured":"Feng J, Dong H, Duan H (2026) Development and validation of a machine learning stratified prediction model for early warning of anti-tuberculosis drug-induced liver injury risk based on real-world data: a retrospective cohort study. BMC Med Inf Decis Mak 26(1):74. https:\/\/doi.org\/10.1186\/s12911-026-03373-9","journal-title":"BMC Med Inf Decis Mak"},{"key":"5686_CR144","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2147\/DDDT.S495555","volume":"19","author":"Y Zeng","year":"2025","unstructured":"Zeng Y, Lu H, Li S, Shi QZ, Liu L, Gong YQ et al (2025) Risk prediction of liver injury in pediatric tuberculosis treatment: development of an automated machine learning model. Drug Des Devel Ther 19:239\u2013250. https:\/\/doi.org\/10.2147\/DDDT.S495555","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"5686_CR145","doi-asserted-by":"publisher","first-page":"e29226","DOI":"10.2196\/29226","volume":"9","author":"T Zhong","year":"2021","unstructured":"Zhong T, Zhuang Z, Dong X, Wong KH, Wong WT, Wang J et al (2021) Predicting antituberculosis drug-induced liver injury using an interpretable machine learning method: model development and validation study. JMIR Med Inf 9(7):e29226. https:\/\/doi.org\/10.2196\/29226","journal-title":"JMIR Med Inf"},{"issue":"3","key":"5686_CR146","doi-asserted-by":"publisher","first-page":"246","DOI":"10.4258\/hir.2023.29.3.246","volume":"29","author":"S Heo","year":"2023","unstructured":"Heo S, Yu JY, Kang EA, Shin H, Ryu K, Kim C et al (2023) Development and verification of time-series deep learning for drug-induced liver injury detection in patients taking angiotensin II receptor blockers: a multicenter distributed research network approach. Healthc Inf Res 29(3):246\u2013255. https:\/\/doi.org\/10.4258\/hir.2023.29.3.246","journal-title":"Healthc Inf Res"},{"key":"5686_CR147","doi-asserted-by":"publisher","first-page":"103302","DOI":"10.1016\/j.artmed.2025.103302","volume":"171","author":"GA Castro","year":"2026","unstructured":"Castro GA, Barioto LG, Cao YH, Silva RM, Caseli HM, Machado-Neto JA et al (2026) Automated machine learning in medical research: a systematic literature mapping study. Artif Intell Med 171:103302. https:\/\/doi.org\/10.1016\/j.artmed.2025.103302","journal-title":"Artif Intell Med"},{"issue":"5","key":"5686_CR148","doi-asserted-by":"publisher","first-page":"247","DOI":"10.14740\/gr2062","volume":"18","author":"T Suenghataiphorn","year":"2025","unstructured":"Suenghataiphorn T, Boonpiraks K, Prasitsumrit V, Kulthamrongsri N, Danpanichkul P (2025) Enabling drug-induced liver injury surveillance through automated medication extraction from clinical notes: a medical information mart for intensive care IV real-world large language models validation study. Gastroenterol Res 18(5):247\u2013253. https:\/\/doi.org\/10.14740\/gr2062","journal-title":"Gastroenterol Res"},{"issue":"1","key":"5686_CR149","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12931-026-03608-3","volume":"27","author":"Q Liu","year":"2026","unstructured":"Liu Q, Wang C, Si G, He J (2026) Integrated multiomics profiling predicts anti-tuberculosis drug-induced liver injury. Respir Res 27(1):169. https:\/\/doi.org\/10.1186\/s12931-026-03608-3","journal-title":"Respir Res"},{"issue":"1","key":"5686_CR150","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12879-017-2330-z","volume":"17","author":"A Abbara","year":"2017","unstructured":"Abbara A, Chitty S, Roe JK, Ghani R, Collin SM, Ritchie A et al (2017) Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infect Dis 17(1):231. https:\/\/doi.org\/10.1186\/s12879-017-2330-z","journal-title":"BMC Infect Dis"},{"issue":"6","key":"5686_CR151","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1164\/rccm.201105-0850OC","volume":"185","author":"A Singanayagam","year":"2012","unstructured":"Singanayagam A, Sridhar S, Dhariwal J, Abdel-Aziz D, Munro K, Connell DW et al (2012) A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am J Respir Crit Care Med 185(6):653\u2013659. https:\/\/doi.org\/10.1164\/rccm.201105-0850OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"5686_CR152","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jinf.2020.09.038","volume":"82","author":"B Patterson","year":"2021","unstructured":"Patterson B, Abbara A, Collin S, Henderson M, Shehata M, Gorgui-Naguib H et al (2021) Predicting drug-induced liver injury from anti-tuberculous medications by early monitoring of liver tests. J Infect 82(2):240\u2013244. https:\/\/doi.org\/10.1016\/j.jinf.2020.09.038","journal-title":"J Infect"},{"key":"5686_CR153","unstructured":"Jogu P, Zubair M, Minter DA (2026) Liver function tests. StatPearls Publishing, Treasure Island, FL. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482489\/. Accessed 2 September 2026"},{"issue":"6","key":"5686_CR154","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1164\/rccm.201112-2174ED","volume":"185","author":"JJ Saukkonen","year":"2012","unstructured":"Saukkonen JJ, Powell K, Jereb JA (2012) Monitoring for tuberculosis drug hepatotoxicity: moving from opinion to evidence. Am J Respir Crit Care Med 185(6):598\u2013599. https:\/\/doi.org\/10.1164\/rccm.201112-2174ED","journal-title":"Am J Respir Crit Care Med"},{"key":"5686_CR155","unstructured":"Corcorran MA, Kim HN, Spach DH Monitoring during and after HCV treatment., Hepatitis C, Online (2023) https:\/\/www.hepatitisc.uw.edu\/go\/treatment-infection\/monitoring\/core-concept\/all. Accessed 10 May 2026"},{"issue":"4","key":"5686_CR156","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/cid\/ciz241","volume":"70","author":"GCY Lui","year":"2020","unstructured":"Lui GCY, Wong NS, Wong RYK, Tse YK, Wong VWS, Leung CC et al (2020) Antiviral therapy for hepatitis B prevents liver injury in patients with tuberculosis and hepatitis B coinfection. Clin Infect Dis 70(4):660\u2013666. https:\/\/doi.org\/10.1093\/cid\/ciz241","journal-title":"Clin Infect Dis"},{"key":"5686_CR157","doi-asserted-by":"publisher","first-page":"197664","DOI":"10.1016\/j.virusres.2019.197664","volume":"270","author":"J Lian","year":"2019","unstructured":"Lian J, Hu P, Lu Y, Liu Y, Wang X, Zhang Y et al (2019) Prophylactic antiviral treatment reduces the incidence of liver failure among patients coinfected with Mycobacterium tuberculosis and hepatitis B virus. Virus Res 270:197664. https:\/\/doi.org\/10.1016\/j.virusres.2019.197664","journal-title":"Virus Res"},{"issue":"2","key":"5686_CR158","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","volume":"83","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver (2025) EASL clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 83(2):502\u2013583. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.018","journal-title":"J Hepatol"},{"key":"5686_CR159","volume-title":"Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection","author":"World Health Organization","year":"2024","unstructured":"World Health Organization (2024) Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. World Health Organization, Geneva. https:\/\/www.who.int\/publications\/i\/item\/9789240090903 Accessed 2 September 2026"},{"issue":"6","key":"5686_CR160","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1093\/jac\/dkz068","volume":"74","author":"M Cerrone","year":"2019","unstructured":"Cerrone M, Alfarisi O, Neary M, Marzinke MA, Parsons TL, Owen A et al (2019) Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. J Antimicrob Chemother 74(6):1670\u20131678. https:\/\/doi.org\/10.1093\/jac\/dkz068","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"5686_CR161","doi-asserted-by":"publisher","first-page":"e720","DOI":"10.1093\/cid\/ciaf732","volume":"82","author":"EC Osuala","year":"2026","unstructured":"Osuala EC, Nkuhairwe IN, Letsoalo MP, Naidoo K, Perumal R, Rooney JF et al (2026) Pharmacokinetics of twice-daily tenofovir alafenamide in adults with HIV-associated tuberculosis on bictegravir\/emtricitabine\/tenofovir alafenamide and rifampicin. Clin Infect Dis 82(4):e720\u2013e727. https:\/\/doi.org\/10.1093\/cid\/ciaf732","journal-title":"Clin Infect Dis"},{"key":"5686_CR162","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.ijid.2020.09.1423","volume":"100","author":"TCS Martin","year":"2020","unstructured":"Martin TCS, Hill LA, Tang ME, Balcombe SM (2020) Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: a retrospective observational study. Int J Infect Dis 100:470\u2013472. https:\/\/doi.org\/10.1016\/j.ijid.2020.09.1423","journal-title":"Int J Infect Dis"},{"issue":"11","key":"5686_CR163","doi-asserted-by":"publisher","first-page":"e25844","DOI":"10.1002\/jia2.25844","volume":"24","author":"BH Liou","year":"2021","unstructured":"Liou BH, Cheng CN, Lin YT, Lin YJ, Chuang YC, Lin KY et al (2021) Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir\/emtricitabine\/tenofovir alafenamide. J Int AIDS Soc 24(11):e25844. https:\/\/doi.org\/10.1002\/jia2.25844","journal-title":"J Int AIDS Soc"},{"key":"5686_CR164","unstructured":"University of Liverpool (2026) HEP drug interactions database. University of Liverpool. https:\/\/www.hep-druginteractions.org. Accessed 2 September 2026"},{"issue":"3","key":"5686_CR165","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/bcp.15056","volume":"88","author":"MM Parvez","year":"2022","unstructured":"Parvez MM, Kalkisim S, Nguyen PTT, Jung JA, Park JK, Ghim JL et al (2022) Para-aminosalicylic acid significantly reduced tenofovir exposure in human subjects: mismatched findings from in vitro to in vivo translational research. Br J Clin Pharmacol 88(3):1159\u20131169. https:\/\/doi.org\/10.1111\/bcp.15056","journal-title":"Br J Clin Pharmacol"},{"key":"5686_CR166","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ijid.2020.06.037","volume":"97","author":"TR Cressey","year":"2020","unstructured":"Cressey TR, Siriprakaisil O, Kubiak RW, Klinbuayaem V, Sukrakanchana PO, Quame-Amaglo J et al (2020) Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate. Int J Infect Dis 97:365\u2013370. https:\/\/doi.org\/10.1016\/j.ijid.2020.06.037","journal-title":"Int J Infect Dis"},{"issue":"11","key":"5686_CR167","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1177\/0091270006293304","volume":"46","author":"JH Yan","year":"2006","unstructured":"Yan JH, Bifano M, Olsen S, Smith RA, Zhang D, Grasela DM et al (2006) Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. J Clin Pharmacol 46(11):1250\u20131258. https:\/\/doi.org\/10.1177\/0091270006293304","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"5686_CR168","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3390\/biomedicines9040426","volume":"9","author":"M Drozdzik","year":"2021","unstructured":"Drozdzik M, Drozdzik M, Oswald S (2021) Membrane carriers and transporters in kidney physiology and disease. Biomedicines 9(4):426. https:\/\/doi.org\/10.3390\/biomedicines9040426","journal-title":"Biomedicines"},{"issue":"7","key":"5686_CR169","doi-asserted-by":"publisher","first-page":"159","DOI":"10.21037\/atm.2017.03.69","volume":"5","author":"AS Woo","year":"2017","unstructured":"Woo AS, Kwok R, Ahmed T (2017) Alpha-interferon treatment in hepatitis B. Ann Transl Med 5(7):159. https:\/\/doi.org\/10.21037\/atm.2017.03.69","journal-title":"Ann Transl Med"},{"issue":"2","key":"5686_CR170","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/bcp.13095","volume":"83","author":"S Talavera Pons","year":"2017","unstructured":"Talavera Pons S, Boyer A, Lamblin G, Chennell P, Ch\u00e2tenet FT, Nicolas C et al (2017) Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. Br J Clin Pharmacol 83(2):269\u2013293. https:\/\/doi.org\/10.1111\/bcp.13095","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"5686_CR171","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s40262-019-00774-0","volume":"58","author":"EJ Smolders","year":"2019","unstructured":"Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM (2019) Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations: a 2019 update. Clin Pharmacokinet 58(10):1237\u20131263. https:\/\/doi.org\/10.1007\/s40262-019-00774-0","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"5686_CR172","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cpt.1072","volume":"104","author":"JD Lutz","year":"2018","unstructured":"Lutz JD, Kirby BJ, Wang L, Song Q, Ling J, Massetto B et al (2018) Cytochrome P450 3A induction predicts P-glycoprotein induction; part 2: prediction of decreased substrate exposure after rifabutin or carbamazepine. Clin Pharmacol Ther 104(6):1191\u20131198. https:\/\/doi.org\/10.1002\/cpt.1072","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"5686_CR173","doi-asserted-by":"publisher","first-page":"ofad237","DOI":"10.1093\/ofid\/ofad237","volume":"10","author":"A Ashkin","year":"2023","unstructured":"Ashkin A, Alexis A, Ninneman M, Tresgallo RR, Ashkin D, Peloquin CA (2023) Concomitant treatment of tuberculosis and hepatitis C virus in coinfected patients using serum drug concentration monitoring. Open Forum Infect Dis 10(6):ofad237. https:\/\/doi.org\/10.1093\/ofid\/ofad237","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"5686_CR174","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00228-001-0396-3","volume":"57","author":"X Wen","year":"2002","unstructured":"Wen X, Wang JS, Neuvonen PJ, Backman JT (2002) Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol 57(11):799\u2013804. https:\/\/doi.org\/10.1007\/s00228-001-0396-3","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"5686_CR175","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1124\/dmd.117.077834","volume":"46","author":"R Sangana","year":"2018","unstructured":"Sangana R, Gu H, Chun DY, Einolf HJ (2018) Evaluation of clinical drug interaction potential of clofazimine using static and dynamic modeling approaches. Drug Metab Dispos 46(1):26\u201332. https:\/\/doi.org\/10.1124\/dmd.117.077834","journal-title":"Drug Metab Dispos"},{"key":"5686_CR176","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.tube.2015.08.004","volume":"96","author":"LH Te Brake","year":"2016","unstructured":"Te Brake LH, Russel FG, van den Heuvel JJ, de Knegt GJ, de Steenwinkel JE, Burger DM et al (2016) Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters. Tuberculosis (Edinb) 96:150\u2013157. https:\/\/doi.org\/10.1016\/j.tube.2015.08.004","journal-title":"Tuberculosis (Edinb)"},{"issue":"10","key":"5686_CR177","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1128\/AAC.00509-16","volume":"60","author":"S Mallikaarjun","year":"2016","unstructured":"Mallikaarjun S, Wells C, Petersen C, Paccaly A, Shoaf SE, Patil S et al (2016) Delamanid coadministered with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects. Antimicrob Agents Chemother 60(10):5976\u20135985. https:\/\/doi.org\/10.1128\/AAC.00509-16","journal-title":"Antimicrob Agents Chemother"},{"key":"5686_CR178","unstructured":"World Health Organization (2018) Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. World Health Organization. https:\/\/www.who.int\/publications\/i\/item\/9789241550345. Accessed 2 September 2026"},{"issue":"6","key":"5686_CR179","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1007\/s43440-022-00434-4","volume":"74","author":"M Pazgan-Simon","year":"2022","unstructured":"Pazgan-Simon M, Kucharska M, G\u00f3rka-Dynysiewicz J, Simon K (2022) Impact of SARS CoV-2\/COVID-19 infection on the course of advanced chronic liver disease and hepatocellular carcinoma. Pharmacol Rep 74(6):1306\u20131314. https:\/\/doi.org\/10.1007\/s43440-022-00434-4","journal-title":"Pharmacol Rep"},{"issue":"19","key":"5686_CR180","doi-asserted-by":"publisher","first-page":"5760","DOI":"10.3748\/wjg.v20.i19.5760","volume":"20","author":"N Kumar","year":"2014","unstructured":"Kumar N, Kedarisetty CK, Kumar S, Khillan V, Sarin SK (2014) Antitubercular therapy in patients with cirrhosis: challenges and options. World J Gastroenterol 20(19):5760\u20135772. https:\/\/doi.org\/10.3748\/wjg.v20.i19.5760","journal-title":"World J Gastroenterol"},{"issue":"295","key":"5686_CR181","doi-asserted-by":"publisher","first-page":"198","DOI":"10.31729\/jnma.v64i295.9340","volume":"64","author":"PS Tiwari","year":"2025","unstructured":"Tiwari PS, Thapa P (2025) Management of hepatotoxicity and utilization of antitubercular drugs in chronic liver disease: a narrative review. J Nepal Med Assoc 64(295):198\u2013205. https:\/\/doi.org\/10.31729\/jnma.v64i295.9340","journal-title":"J Nepal Med Assoc"},{"issue":"3","key":"5686_CR182","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jceh.2012.07.007","volume":"2","author":"RK Dhiman","year":"2012","unstructured":"Dhiman RK, Saraswat VA, Rajekar H, Reddy C, Chawla YK (2012) A guide to the management of tuberculosis in patients with chronic liver disease. J Clin Exp Hepatol 2(3):260\u2013270. https:\/\/doi.org\/10.1016\/j.jceh.2012.07.007","journal-title":"J Clin Exp Hepatol"},{"issue":"2","key":"5686_CR183","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5588\/ijtldopen.24.0498","volume":"2","author":"O Kirakosyan","year":"2025","unstructured":"Kirakosyan O, Reimann M, Andersen AB, Bjarnason A, Bakos \u00c1, Dyrhol-Riise AM et al (2025) Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe. IJTLD Open 2(2):101\u2013106. https:\/\/doi.org\/10.5588\/ijtldopen.24.0498","journal-title":"IJTLD Open"},{"key":"5686_CR184","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4103\/ijpvm.ijpvm_81_22","volume":"14","author":"A Talebi","year":"2023","unstructured":"Talebi A, Soltani R, Khorvash F, Jouabadi SM (2023) The effectiveness of silymarin in the prevention of anti-tuberculosis drug-induced hepatotoxicity: a randomized controlled clinical trial. Int J Prev Med 14:48. https:\/\/doi.org\/10.4103\/ijpvm.ijpvm_81_22","journal-title":"Int J Prev Med"},{"key":"5686_CR185","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12906-015-0861-7","volume":"15","author":"C Luangchosiri","year":"2015","unstructured":"Luangchosiri C, Thakkinstian A, Chitphuk S, Stitchantrakul W, Petraksa S, Sobhonslidsuk A (2015) A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. BMC Complement Altern Med 15:334. https:\/\/doi.org\/10.1186\/s12906-015-0861-7","journal-title":"BMC Complement Altern Med"},{"issue":"2","key":"5686_CR186","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/jgh.13070","volume":"31","author":"S Zhang","year":"2016","unstructured":"Zhang S, Pan H, Peng X et al (2016) Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: a randomized controlled trial. J Gastroenterol Hepatol 31(2):409\u2013416. https:\/\/doi.org\/10.1111\/jgh.13070","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"5686_CR187","first-page":"247","volume":"15","author":"M Marjani","year":"2016","unstructured":"Marjani M, Baghaei P, Kazempour Dizaji M et al (2016) Evaluation of hepatoprotective effect of silymarin among under treatment tuberculosis patients: a randomized clinical trial. Iran J Pharm Res 15(1):247\u2013252","journal-title":"Iran J Pharm Res"},{"issue":"4","key":"5686_CR188","doi-asserted-by":"publisher","first-page":"475","DOI":"10.5588\/ijtld.14.0579","volume":"19","author":"NH Chu","year":"2015","unstructured":"Chu NH, Li L, Zhang X, Gu J, Du YD, Cai C et al (2015) Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease. Int J Tuberc Lung Dis 19(4):475\u2013480. https:\/\/doi.org\/10.5588\/ijtld.14.0579","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"5686_CR189","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1097\/MEG.0b013e32833aa11b","volume":"22","author":"S Baniasadi","year":"2010","unstructured":"Baniasadi S, Eftekhari P, Tabarsi P, Fahimi F, Raoufy MR, Masjedi MR et al (2010) Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol 22(10):1235\u20131238. https:\/\/doi.org\/10.1097\/MEG.0b013e32833aa11b","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"5686_CR190","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s12072-023-10633-7","volume":"18","author":"Y Mao","year":"2024","unstructured":"Mao Y, Ma S, Liu C, Liu X, Su M, Li D et al (2024) Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update. Hepatol Int 18(2):384\u2013419. https:\/\/doi.org\/10.1007\/s12072-023-10633-7","journal-title":"Hepatol Int"},{"issue":"4","key":"5686_CR191","doi-asserted-by":"publisher","first-page":"e0283726","DOI":"10.1371\/journal.pone.0283726","volume":"18","author":"JE Guti\u00e9rrez-Virgen","year":"2023","unstructured":"Guti\u00e9rrez-Virgen JE, Pi\u00f1a-Pozas M, Hern\u00e1ndez-Tob\u00edas EA, Taja-Chayeb L, L\u00f3pez-Gonz\u00e1lez ML, Meraz-R\u00edos MA et al (2023) NAT2 global landscape: genetic diversity and acetylation statuses from a systematic review. PLoS ONE 18(4):e0283726. https:\/\/doi.org\/10.1371\/journal.pone.0283726","journal-title":"PLoS ONE"},{"issue":"1","key":"5686_CR192","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12863-024-01286-y","volume":"25","author":"R Mahajan","year":"2024","unstructured":"Mahajan R, Tyagi AK (2024) Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis. BMC Genom Data 25(1):103. https:\/\/doi.org\/10.1186\/s12863-024-01286-y","journal-title":"BMC Genom Data"},{"issue":"1","key":"5686_CR193","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41598-023-38716-3","volume":"25","author":"R Mahajan","year":"2024","unstructured":"Sileshi T, Telele NF, Burkley V, Makonnen E, Aklillu E (2023) Correlation of N-acetyltransferase 2 genotype and acetylation status with plasma isoniazid concentration and its metabolic ratio in Ethiopian tuberculosis patients. Sci Rep 13(1):11438. https:\/\/doi.org\/10.1038\/s41598-023-38716-3","journal-title":"BMC Genom Data"},{"issue":"2","key":"5686_CR194","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/cid\/cis353","volume":"55","author":"JG Pasipanodya","year":"2012","unstructured":"Pasipanodya JG, Srivastava S, Gumbo T (2012) Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 55(2):169\u2013177. https:\/\/doi.org\/10.1093\/cid\/cis353","journal-title":"Clin Infect Dis"},{"issue":"5","key":"5686_CR195","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","volume":"69","author":"J Azuma","year":"2013","unstructured":"Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K et al (2013) NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol 69(5):1091\u20131101. https:\/\/doi.org\/10.1007\/s00228-012-1429-9","journal-title":"Eur J Clin Pharmacol"},{"key":"5686_CR196","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.2147\/DDDT.S87131","volume":"9","author":"JA Jung","year":"2015","unstructured":"Jung JA, Kim TE, Lee H, Jeong BH, Park HY, Jeon K et al (2015) A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis. Drug Des Devel Ther 9:5433\u20135438. https:\/\/doi.org\/10.2147\/DDDT.S87131","journal-title":"Drug Des Devel Ther"},{"key":"5686_CR197","doi-asserted-by":"publisher","first-page":"1772312","DOI":"10.3389\/fpubh.2026.1772312","volume":"14","author":"M Kantared","year":"2026","unstructured":"Kantared M, Permsuwan U (2026) Cost-utility analysis of stratified isoniazid dosing by NAT2 genotype compared with isoniazid standard regimen for new patients with pulmonary tuberculosis in Thailand. Front Public Health 14:1772312. https:\/\/doi.org\/10.3389\/fpubh.2026.1772312","journal-title":"Front Public Health"},{"issue":"12","key":"5686_CR198","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1093\/cid\/ciz1212","volume":"71","author":"NE Rens","year":"2020","unstructured":"Rens NE, Uyl-de Groot CA, Goldhaber-Fiebert JD, Croda J, Andrews JR (2020) Cost-effectiveness of a pharmacogenomic test for stratified isoniazid dosing in treatment of active tuberculosis. Clin Infect Dis 71(12):3136\u20133143. https:\/\/doi.org\/10.1093\/cid\/ciz1212","journal-title":"Clin Infect Dis"},{"issue":"11","key":"5686_CR199","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1164\/rccm.202103-0564OC","volume":"204","author":"R Verma","year":"2021","unstructured":"Verma R, Patil S, Zhang N, Moreira FMF, Vitorio MT, Santos ADS et al (2021) A rapid pharmacogenomic assay to detect NAT2 polymorphisms and guide isoniazid dosing for tuberculosis treatment. Am J Respir Crit Care Med 204(11):1317\u20131326. https:\/\/doi.org\/10.1164\/rccm.202103-0564OC","journal-title":"Am J Respir Crit Care Med"},{"key":"5686_CR200","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ncrna.2025.08.001","volume":"15","author":"ES Katayama","year":"2025","unstructured":"Katayama ES, Hue JJ, Loftus AW, Ali SA, Graor HJ, Rothermel LD et al (2025) Stability of microRNAs in serum and plasma reveal promise as a circulating biomarker. Noncoding RNA Res 15:132\u2013141. https:\/\/doi.org\/10.1016\/j.ncrna.2025.08.001","journal-title":"Noncoding RNA Res"},{"issue":"4","key":"5686_CR201","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ymeth.2010.01.032","volume":"50","author":"EM Kroh","year":"2010","unstructured":"Kroh EM, Parkin RK, Mitchell PS, Tewari M (2010) Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50(4):298\u2013301. https:\/\/doi.org\/10.1016\/j.ymeth.2010.01.032","journal-title":"Methods"},{"issue":"1","key":"5686_CR202","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/cimb45010006","volume":"45","author":"E Cione","year":"2022","unstructured":"Cione E, Abrego Guandique DM, Caroleo MC, Luciani F, Colosimo M, Cannataro R (2022) Liver damage and microRNAs: an update. Curr Issues Mol Biol 45(1):78\u201391. https:\/\/doi.org\/10.3390\/cimb45010006","journal-title":"Curr Issues Mol Biol"},{"issue":"8","key":"5686_CR203","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1111\/bcp.14736","volume":"87","author":"SAE Rupprechter","year":"2021","unstructured":"Rupprechter SAE, Sloan DJ, Oosthuyzen W, Bachmann TT, Hill AT, Dhaliwal K et al (2021) MicroRNA-122 and cytokeratin-18 have potential as a biomarkers of drug-induced liver injury in European and African patients on treatment for mycobacterial infection. Br J Clin Pharmacol 87(8):3206\u20133217. https:\/\/doi.org\/10.1111\/bcp.14736","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"5686_CR204","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1111\/bcp.15661","volume":"89","author":"MS Moosa","year":"2023","unstructured":"Moosa MS, Russomanno G, Dorfman JR, Gunter H, Patel C, Costello E et al (2023) Analysis of serum microRNA-122 in a randomized controlled trial of N-acetylcysteine for treatment of antituberculosis drug-induced liver injury. Br J Clin Pharmacol 89(6):1844\u20131851. https:\/\/doi.org\/10.1111\/bcp.15661","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"5686_CR205","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/hep.29802","volume":"69","author":"RJ Church","year":"2019","unstructured":"Church RJ, Kullak-Ublick GA, Aubrecht J, Bonkovsky HL, Chalasani N, Fontana RJ et al (2019) Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort. Hepatology 69(2):760\u2013773. https:\/\/doi.org\/10.1002\/hep.29802","journal-title":"Hepatology"},{"issue":"2","key":"5686_CR206","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1111\/j.1365-2893.2011.01536.x","volume":"19","author":"O Waidmann","year":"2012","unstructured":"Waidmann O, Bihrer V, Pleli T, Farnik H, Berger A, Zeuzem S et al (2012) Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat 19(2):e58\u2013e65. https:\/\/doi.org\/10.1111\/j.1365-2893.2011.01536.x","journal-title":"J Viral Hepat"},{"issue":"1","key":"5686_CR207","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12879-023-08016-2","volume":"24","author":"WM Ezzat","year":"2024","unstructured":"Ezzat WM, Amr KS, Tawfeek S, Elbatae H, Bayomi EA, Heiba A et al (2024) Serum microRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment. BMC Infect Dis 24(1):67. https:\/\/doi.org\/10.1186\/s12879-023-08016-2","journal-title":"BMC Infect Dis"},{"issue":"11","key":"5686_CR208","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1007\/s00204-021-03121-0","volume":"95","author":"S Korver","year":"2021","unstructured":"Korver S, Bowen J, Pearson K, Gonzalez RJ, French N, Park K et al (2021) The application of cytokeratin-18 as a biomarker for drug-induced liver injury. Arch Toxicol 95(11):3435\u20133448. https:\/\/doi.org\/10.1007\/s00204-021-03121-0","journal-title":"Arch Toxicol"},{"issue":"10","key":"5686_CR209","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1111\/bcp.15807","volume":"89","author":"B He","year":"2023","unstructured":"He B, Cheng X, Xiang HR, Li Y, Zhang QZ, Peng WX et al (2023) Glutamate dehydrogenase combined with ferrochelatase as a biomarker of liver injury induced by antituberculosis drugs. Br J Clin Pharmacol 89(10):3092\u20133104. https:\/\/doi.org\/10.1111\/bcp.15807","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05686-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05686-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05686-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:12:14Z","timestamp":1790741534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-026-05686-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":209,"alternative-id":["5686"],"URL":"https:\/\/doi.org\/10.1007\/s10096-026-05686-z","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"8 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}